193 related articles for article (PubMed ID: 27802290)
1. Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.
Kronimus Y; Albus A; Balzer-Geldsetzer M; Straub S; Semler E; Otto M; Klotsche J; Dodel R; ; Mengel D
PLoS One; 2016; 11(11):e0164953. PubMed ID: 27802290
[TBL] [Abstract][Full Text] [Related]
2. Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein.
Albus A; Gold M; Bach JP; Burg-Roderfeld M; Jördens M; Kirchhein Y; Kronimus Y; Mengel D; Zerr I; Dodel R
PLoS One; 2018; 13(8):e0202954. PubMed ID: 30157279
[TBL] [Abstract][Full Text] [Related]
3. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
[TBL] [Abstract][Full Text] [Related]
4. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
[TBL] [Abstract][Full Text] [Related]
5. Neuroinflammation and protein pathology in Parkinson's disease dementia.
Kouli A; Camacho M; Allinson K; Williams-Gray CH
Acta Neuropathol Commun; 2020 Dec; 8(1):211. PubMed ID: 33272323
[TBL] [Abstract][Full Text] [Related]
6. Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays.
Heinzel S; Gold M; Deuschle C; Bernhard F; Maetzler W; Berg D; Dodel R
PLoS One; 2014; 9(12):e114566. PubMed ID: 25470145
[TBL] [Abstract][Full Text] [Related]
7. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.
Buongiorno M; Antonelli F; Compta Y; Fernandez Y; Pavia J; Lomeña F; Ríos J; Ramírez I; García JR; Soler M; Cámara A; Fernández M; Basora M; Salazar F; Sanchez-Etayo G; Valldeoriola F; Barrio JR; Marti MJ
J Alzheimers Dis; 2017; 55(3):1261-1272. PubMed ID: 27814297
[TBL] [Abstract][Full Text] [Related]
8. Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls.
Maetzler W; Apel A; Langkamp M; Deuschle C; Dilger SS; Stirnkorb JG; Schulte C; Schleicher E; Gasser T; Berg D
PLoS One; 2014; 9(2):e88604. PubMed ID: 24586351
[TBL] [Abstract][Full Text] [Related]
9. Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.
Compta Y; Ibarretxe-Bilbao N; Pereira JB; Junqué C; Bargalló N; Tolosa E; Valldeoriola F; Muñoz E; Camara A; Buongiorno M; Martí MJ
Parkinsonism Relat Disord; 2012 Sep; 18(8):941-7. PubMed ID: 22595621
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.
Compta Y; Martí MJ; Ibarretxe-Bilbao N; Junqué C; Valldeoriola F; Muñoz E; Ezquerra M; Ríos J; Tolosa E
Mov Disord; 2009 Nov; 24(15):2203-10. PubMed ID: 19795497
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease.
Besong-Agbo D; Wolf E; Jessen F; Oechsner M; Hametner E; Poewe W; Reindl M; Oertel WH; Noelker C; Bacher M; Dodel R
Neurology; 2013 Jan; 80(2):169-75. PubMed ID: 23255825
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.
Brudek T; Winge K; Folke J; Christensen S; Fog K; Pakkenberg B; Pedersen LØ
Mol Neurodegener; 2017 Jun; 12(1):44. PubMed ID: 28592329
[TBL] [Abstract][Full Text] [Related]
13. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-β and τ biomarkers in Parkinson's disease-dementia.
Buongiorno M; Compta Y; Martí MJ
J Neurol Sci; 2011 Nov; 310(1-2):25-30. PubMed ID: 21764078
[TBL] [Abstract][Full Text] [Related]
16. Significance of cerebral amyloid angiopathy and other co-morbidities in Lewy body diseases.
Jellinger KA
J Neural Transm (Vienna); 2021 May; 128(5):687-699. PubMed ID: 33928445
[TBL] [Abstract][Full Text] [Related]
17. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
19. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.
Mollenhauer B; Trenkwalder C; von Ahsen N; Bibl M; Steinacker P; Brechlin P; Schindehuette J; Poser S; Wiltfang J; Otto M
Dement Geriatr Cogn Disord; 2006; 22(3):200-8. PubMed ID: 16899997
[TBL] [Abstract][Full Text] [Related]
20. Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
Jellinger KA
Exp Neurol; 2011 Jan; 227(1):13-8. PubMed ID: 20965169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
